lung
transplant
ltx
increas
treatment
option
end
stage
lung
diseas
although
mortal
post
transplant
decreas
modern
surgic
techniqu
pharmaceut
regim
mortal
report
around
infect
predomin
caus
death
first
year
post
constant
exposur
environ
inhal
microorgan
togeth
denerv
reduc
ciliari
transport
decreas
cough
increas
risk
lung
infect
moreov
heavi
immunosuppress
therapi
lead
decreas
immun
defens
bronchoalveolar
lavag
bal
includ
microbiolog
cultur
pcr
perform
lung
transplant
patient
surveil
respons
clinic
symptom
guid
antibiot
therapi
microbiolog
panorama
differ
geograph
region
especi
regard
multidrug
resist
bacteria
mdr
import
map
local
epidemiolog
previou
studi
microbiolog
lung
transplant
patient
focus
infect
rather
total
panorama
microbiolog
moreov
studi
lung
infect
lung
transplant
patient
singl
center
report
small
number
patient
sweden
ltx
perform
two
center
univers
hospit
lund
sahlgrenska
univers
hospit
gothenburg
primari
aim
nationwid
prospect
studi
examin
microbiolog
panorama
balf
lung
transplant
patient
sweden
post
transplant
compar
find
patient
without
sign
lung
infect
prospect
cohort
studi
includ
adult
patient
accept
ltx
may
decemb
gothenburg
octob
decemb
lund
patient
year
age
patient
follow
site
exclud
patient
follow
year
transplant
written
inform
consent
obtain
studi
particip
studi
approv
region
ethic
committe
reg
nr
perform
accord
ethic
standard
declar
helsinki
later
amend
standard
protocol
immunosuppress
includ
induct
therapi
atg
globulin
follow
tacrolimu
ciclosporin
mycophenol
mofetil
steroid
lung
transplant
recipi
receiv
pneumocysti
prophylaxi
cytomegaloviru
cmv
prophylaxi
valganciclovir
given
particip
except
patient
gothenburg
donor
recipi
cmv
neg
lund
patient
receiv
fungal
prophylaxi
fluconazol
month
wherea
patient
gothenburg
receiv
oral
nystatin
least
week
standard
periop
antibiot
treatment
cefotaxim
gothenburg
imipenem
lund
modif
termin
antibiot
treatment
done
accord
periop
donor
recipi
cultur
ltx
procedur
bacteri
fungal
cultur
obtain
donor
recipi
lung
recipi
follow
first
year
ltx
routin
bronchoscopi
month
post
transplant
addit
bronchoscopi
perform
respons
clinic
symptom
bal
procedur
follow
standard
protocol
microbiolog
analys
perform
microbiolog
depart
univers
hospit
sahlgrenska
univers
hospit
accord
standard
balf
sampl
analyz
bacteri
fungal
cultur
includ
microscopi
fungal
element
pcr
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
pneumophila
mdr
pseudomona
aeruginosa
defin
resist
meropenem
least
one
agent
three
categori
antibiot
definit
base
criteria
publish
magiorako
et
modif
resist
meropenem
present
panel
airway
virus
analyz
multiplex
pcr
includ
parainfluenza
respiratori
syncyti
viru
rsv
influenza
b
adenoviru
metapneumoviru
coronaviru
oc
enteroviru
rhinoviru
lund
addit
pcr
herp
simplex
viru
hsv
perform
method
presenc
pneumocysti
jiroveci
analyz
immunofluoresc
balf
cmv
blood
plasma
determin
quantit
pcr
balf
sampl
lund
routin
stain
cultur
mycobacteria
balf
sampl
gothenburgh
analyz
mycobacteria
pretranspl
histori
mycobacteri
infect
transbronchi
biopsi
tbb
analyz
depart
patholog
univers
hospit
sahlgrenska
univers
hospit
reject
defin
grade
accord
intern
societi
heart
lung
bronchoscopi
posit
microbiolog
find
classifi
pneumonia
presenc
least
one
follow
clinic
criteria
new
increas
cough
dyspnea
increas
sputa
fever
worsen
ga
exchang
white
blood
cell
count
togeth
new
within
day
bronchoscopi
infiltr
chest
radiolog
ct
scan
bronchoscopi
posit
microbiolog
find
classifi
tracheobronch
presenc
clinic
sign
infiltr
chest
radiolog
one
follow
macroscop
endobronchi
abnorm
inflam
endobronchi
mucosa
endobronchi
lesion
whiteyellow
withwithout
necrot
chang
purul
secret
pneumonia
tracheobronch
refer
bronchoscopi
sign
infect
text
cmv
pneumon
defin
airway
symptom
describ
cmv
copiesml
blood
find
inclus
bodi
tbb
minimum
day
lung
infect
allow
consid
new
episod
bronchoscopi
posit
microbiolog
find
classifi
infect
absenc
clinic
andor
radiolog
macroscop
patholog
growth
pharyng
flora
consid
contamin
classifi
neg
microbiolog
clinic
data
record
time
bronchoscopi
studi
protocol
retriev
retrospect
patient
record
time
transplant
categor
month
month
month
month
ltx
microbiolog
find
group
bacteria
bacteria
g
yeast
mold
viru
p
aeruginosa
analyz
separ
numer
data
present
median
rang
rank
sum
test
logist
regress
analysi
varianc
use
assess
distribut
background
factor
among
differ
bacteri
group
lung
infect
time
period
sinc
particip
underw
vari
number
bronchoscopi
studi
sever
patient
recurr
find
pathogen
balf
frequenc
individu
microb
report
total
number
patient
actual
find
group
microbiolog
find
first
year
present
percent
patient
bronchoscopi
within
specifi
time
period
contrast
overal
microbiolog
find
lung
infect
present
number
episod
proport
patient
associ
background
data
gender
age
ltx
type
ltx
underli
diseas
type
immunosuppress
posit
neg
donor
cultur
time
first
lung
infect
estim
cox
regress
statist
test
ci
overlap
less
consid
statist
signific
analys
perform
use
statas
version
window
statacorp
lp
colleg
station
tx
usa
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
spss
version
spss
armonk
ny
usa
total
patient
elig
inclus
consecut
includ
studi
nine
patient
unabl
give
inform
consent
one
patient
declin
particip
one
patient
includ
unknown
reason
nine
patient
die
bronchoscopi
perform
result
patient
gothenburg
lund
prospect
follow
year
ltx
particip
median
age
year
women
underw
doubl
lung
transplant
chronic
obstruct
pulmonari
diseas
copd
common
underli
diseas
detail
patient
characterist
see
tabl
patient
receiv
immunosuppress
ciclosporin
tacrolimu
patient
cystic
fibrosi
like
receiv
tacrolimu
ciclosporin
vs
p
differ
choic
immunosuppress
depend
background
diagnosi
found
studi
period
bronchoscopi
perform
median
three
per
patient
rang
two
hundr
eleven
bronchoscopi
routin
procedur
wherea
perform
clinic
indic
bronchoscopi
distribut
first
year
shown
figur
sampl
analyz
bacteri
fungal
growth
includ
microscopi
fungal
element
pcr
mycoplasma
chlamydia
legionella
multiplex
pcr
airway
virus
analyz
sampl
pneumocysti
analyz
sampl
nineteen
patient
total
studi
popul
neg
balf
culturespcr
throughout
follow
remain
patient
posit
microbiolog
patient
episod
sign
lung
infect
patient
least
one
episod
sign
lung
infect
patient
least
one
pneumonia
patient
least
one
episod
tracheobronch
pneumonia
total
balf
sampl
neg
microbiolog
result
includ
sampl
growth
pharyng
flora
figur
exclud
analys
remain
sampl
posit
microbiolog
find
balf
bacteri
growth
fungal
growth
posit
viral
pcr
singl
microb
found
balf
sampl
wherea
balf
combin
bacteria
fungi
viru
bronchoscopi
perform
within
month
transplant
find
compar
later
bronchoscopi
vs
p
common
microbiolog
find
candida
albican
p
aeruginosa
coagulas
neg
staphylococcu
patient
respect
see
tabl
microbiolog
find
three
patient
growth
extend
spectrum
esbl
bacteria
balf
two
escherichia
coli
one
enterobact
cloaca
one
patient
multiresist
burkholderia
nine
patient
multiresist
p
aeruginosa
staphylococcu
aureu
mrsa
enterobacteriacea
enterococcu
vre
found
proport
patient
bacteri
find
balf
increas
first
month
declin
figur
yeast
common
within
first
month
ltx
wherea
mold
peak
month
figur
proport
viral
find
increas
time
maximum
patient
month
figur
bacteria
significantli
common
sampl
patient
receiv
immunosuppress
ciclosporin
compar
patient
receiv
tacrolimu
p
contrast
bacteria
found
sampl
patient
receiv
tacrolimu
respect
yield
ci
howev
patient
cystic
fibrosi
frequent
treat
tacrolimu
signific
associ
bacteria
tacrolimu
found
adjust
cystic
fibrosi
ci
signific
differ
note
mold
yeast
viru
p
p
p
respect
analysi
underli
pulmonari
condit
growth
p
aeruginosa
well
bacteria
common
find
patient
cystic
fibrosi
compar
underli
diseas
vs
p
vs
p
respect
patient
defici
significantli
bacteria
vs
p
less
bacteria
vs
p
mold
vs
p
compar
underli
diagnos
patient
underli
pulmonari
fibrosi
bacteria
vs
p
less
growth
p
aeruginosa
balf
vs
p
compar
underli
diagnos
recipi
cultur
obtain
patient
patient
posit
recipi
cultur
sixteen
patient
growth
p
aeruginosa
remain
patient
find
aureu
e
coli
candida
patient
pseudomona
recipi
cultur
subsequ
posit
cultur
pseudomona
point
follow
period
signific
differ
time
first
posit
pseudomona
cultur
found
patient
n
without
n
growth
pseudomona
recipi
cultur
mean
time
posit
pseudomona
cultur
day
respect
p
bronchoscopi
posit
microbiolog
find
patient
clinic
sign
lung
infect
pneumonia
tracheobronch
time
bronchoscopi
balf
sampl
patient
sign
infect
obtain
less
day
apart
thu
consid
lung
infect
episod
left
sampl
sampl
patient
concomit
symptom
consist
pneumonia
tracheobronch
six
sampl
also
sign
acut
reject
tbb
may
add
clinic
present
five
grade
one
grade
remain
balf
sampl
posit
microbiolog
find
regard
infect
figur
balf
patient
concomit
sign
lung
infect
common
fungal
viral
organ
p
aeruginosa
stenotrophomona
coagulas
neg
staphylococcu
aureu
c
albican
aspergillu
fumigatu
rhinoviru
coronaviru
sampl
respect
one
patient
sign
lung
infect
simultan
cmv
copiesml
blood
inclus
bodi
tbb
thu
consid
possibl
cmv
pneumon
median
time
first
episod
sign
lung
infect
day
rang
incid
decreas
time
first
year
ltx
balf
sampl
patient
sign
infect
previou
bronchoscopi
perform
within
studi
remain
sampl
microb
identifi
previou
balf
sampl
reveal
growth
p
aeruginosa
compar
microbiolog
find
without
sign
infect
frequenc
bacteria
bacteria
mold
viru
significantli
differ
tabl
yeast
significantli
frequent
sign
infect
p
howev
candida
found
singl
microb
sampl
sign
lung
infect
concomit
macroscop
find
consist
tracheobronch
fourteen
sampl
obtain
within
month
ltx
sampl
c
albican
total
number
bronchoscopi
sever
microbiolog
find
significantli
differ
sampl
patient
sign
infect
sampl
patient
infect
respect
p
neither
type
immunosuppress
significantli
differ
sampl
patient
without
sign
infect
p
lung
transplant
procedur
bacteri
fungal
cultur
obtain
donor
lung
patient
donor
cultur
posit
patient
growth
bacteria
fungal
growth
frequent
bacteri
fungal
microbiolog
find
donor
lung
aureu
candida
speci
respect
patient
posit
donor
cultur
underw
bronchoscopi
within
month
post
tx
cultur
balf
sampl
yield
microbi
speci
found
donor
cultur
candida
first
month
candida
significantli
common
balf
patient
candida
donor
cultur
compar
balf
patient
donor
lung
neg
candida
respect
p
signific
associ
found
background
factor
time
first
lung
infect
estim
cox
regress
hazard
ratio
hr
posit
donor
cultur
hr
gender
hr
age
ltx
per
increas
hr
singl
vs
doubl
lung
ltx
hr
type
immunosuppress
hr
cystic
fibrosi
compar
underli
diseas
secondari
analysi
patient
microbi
growth
balf
throughout
follow
compar
patient
posit
microbi
find
differ
underli
factor
found
data
report
lung
transplant
patient
undergo
bronchoalveolar
lavag
sever
time
first
year
transplant
studi
microbiolog
lung
transplant
patient
evalu
infect
episod
report
microbiolog
find
balf
prospect
studi
analyz
first
time
total
microbiolog
panorama
found
balf
swedish
lung
transplant
recipi
found
patient
sampl
posit
microbiolog
find
patient
remain
neg
throughout
bronchoscopi
line
find
charlson
et
found
lung
transplant
recipi
higher
bacteri
burden
balf
healthi
control
subject
regardless
underli
indic
transplant
singl
common
bacterium
p
aeruginosa
overal
sampl
sign
lung
infect
p
aeruginosa
previous
well
describ
import
pathogen
lung
transplant
surprisingli
p
aeruginosa
bacteria
significantli
frequent
patient
cystic
fibrosi
fact
studi
particip
underw
vari
number
bronchoscopi
may
result
overrepresent
individu
microb
howev
present
data
proport
patient
microbiolog
find
tri
avoid
bia
bacteria
common
among
patient
receiv
tacrolimu
howev
associ
confound
high
proport
patient
cystic
fibrosi
receiv
tacrolimu
total
number
infect
episod
significantli
differ
patient
receiv
tacrolimu
compar
ciclosporin
line
data
hachem
et
al
zuchelman
et
al
found
differ
frequenc
infect
depend
type
low
preval
mdr
bacteria
studi
reflect
sweden
still
favor
situat
regard
antimicrobi
resist
compar
countri
comparison
kovatz
et
al
describ
mrsa
preval
lung
transplant
patient
first
tebano
et
found
mdr
strain
respiratori
sampl
lung
transplant
patient
recent
public
et
describ
seriou
threat
pose
mdr
bacteria
respiratori
infect
fact
manag
mdr
bacteria
solid
organ
transplant
patient
major
issu
concern
sampl
bacteria
suscept
carbapenem
treatment
mdr
bacteria
found
thu
result
indic
antibiot
prophylaxi
later
empir
antibiot
therapi
present
necessarili
includ
specif
target
mdr
bacteria
swedish
lung
transplant
patient
candida
domin
first
month
line
data
kovat
et
report
high
candida
burden
first
month
ltx
candida
present
sampl
concomit
sign
lung
infect
candida
singl
pathogen
sign
tracheobronch
correspond
incid
candida
tracheobronch
assum
candida
caus
pathogen
number
high
compar
studi
heart
andor
lung
transplant
recipi
overal
incid
invas
candida
infect
describ
tracheobronch
repres
pneumonia
howev
broad
antimicrobi
treatment
first
month
ltx
may
caus
neg
bacteri
balf
cultur
promot
candida
domin
lung
infect
studi
percent
patient
experienc
least
one
episod
symptom
lung
infect
first
year
transplant
limit
studi
take
addit
culturespcr
blood
sputum
nasopharyng
account
anoth
limit
evalu
patient
sampl
sign
infect
true
frequenc
lung
infect
may
underestim
although
result
compar
studi
report
frequenc
lung
infect
incid
lung
infect
studi
decreas
time
similar
result
report
studi
first
three
month
defin
critic
period
infect
lung
transplant
patient
especi
bacteri
consist
previou
studi
found
signific
associ
posit
donor
cultur
later
microbiolog
find
absenc
presenc
lung
microbiolog
panorama
found
balf
patient
clinic
sign
lung
infect
similar
found
sampl
patient
without
symptom
studi
howev
import
note
evalu
probabl
caus
pathogen
sinc
sever
microbiolog
agent
found
balf
patient
sign
lung
infect
caus
microb
difficult
determin
addit
lack
inform
concomit
antimicrobi
treatment
may
interfer
microbiolog
result
well
treatment
specif
pathogen
influenc
clinic
outcom
half
patient
sign
lung
infect
previou
bronchoscopi
microb
found
balf
suggest
microbiolog
result
previou
bronchoscopi
could
guid
antibiot
treatment
half
case
particular
previou
cultur
p
aeruginosa
target
empir
treatment
conclus
major
bronchoscopi
lung
transplant
patient
first
year
ltx
posit
microbiolog
find
often
sever
pathogen
previou
bal
cultur
particular
find
p
aeruginosa
could
guid
empir
treatment
airway
infect
suggest
role
surveil
bronchoscopi
frequenc
mdr
bacteria
low
studi
indic
empir
therapi
need
includ
mdr
bacteria
present
sweden
microbiolog
find
similar
balf
patient
without
sign
lung
infect
result
reinforc
microbiolog
find
evalu
light
clinic
symptom
endobronchi
appear
assess
lung
infect
lung
transplant
patient
author
conflict
interest
declar
relat
materi
present
asa
plan
studi
compil
data
perform
statist
calcul
wrote
manuscript
accord
editori
polici
ethic
consider
author
revis
materi
discuss
result
contribut
final
manuscript
